Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis CEO-Designate Set To Bring More Automation To Drug Discovery

Executive Summary

Vasant Narasimhan, who is replacing Joseph Jimenez as Novartis' CEO next year, is an advocate of automation and artificial intelligence in future drug discovery.

You may also be interested in...



Novartis And Cohen: A View Into Pharma's Policy Concerns As Trump Took Office

As then-Novartis CEO Joe Jimenez worked with former Trump lawyer Michael Cohen on drug pricing issues, the pharma industry was preparing for the debate it's eventually getting to have.

Who's Who In Artificial Intelligence Drug Development

Artificial intelligence companies focused on the life science sector have boomed in the past decade. Many of these firms are working with pharma partners and a small number are pursuing their own drug development pipelines.

2017 – Scrip Readers’ Pharma Year In Review

As we enter a new year, Scrip reviews some of the biggest overall themes which attracted our readers over the last 12 months.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC099420

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel